Self SG - Search Results

1

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. Among authors: self sg. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

2

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC. Gilbert P, et al. Among authors: self sg. J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816. J Infect Dis. 2010. PMID: 20608874 Free PMC article. Clinical Trial.

3

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team. Duerr A, et al. J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4. J Infect Dis. 2012. PMID: 22561365 Free PMC article. Clinical Trial.

4

On the analysis of viral load endpoints in HIV vaccine trials.

Hudgens MG, Hoering A, Self SG. Hudgens MG, et al. Among authors: self sg. Stat Med. 2003 Jul 30;22(14):2281-98. doi: 10.1002/sim.1394. Stat Med. 2003. PMID: 12854093

5

Endpoints in vaccine trials.

Hudgens MG, Gilbert PB, Self SG. Hudgens MG, et al. Among authors: self sg. Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra. Stat Methods Med Res. 2004. PMID: 15068256

6

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. Among authors: self sg. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

7

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND. Moodie Z, et al. Among authors: self sg. Contemp Clin Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19. Contemp Clin Trials. 2006. PMID: 16426900

8

On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.

Wick WD, Gilbert PB, Self SG. Wick WD, et al. Among authors: self sg. PLoS Comput Biol. 2006 Jun 16;2(6):e64. doi: 10.1371/journal.pcbi.0020064. Epub 2006 Jun 16. PLoS Comput Biol. 2006. PMID: 16789816 Free PMC article.

9

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG. Li F, et al. Among authors: self sg. Vaccine. 2006 Nov 17;24(47-48):6893-904. doi: 10.1016/j.vaccine.2006.06.009. Epub 2006 Jun 27. Vaccine. 2006. PMID: 16890329

10

A framework for assessing immunological correlates of protection in vaccine trials.

Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. Qin L, et al. Among authors: self sg. J Infect Dis. 2007 Nov 1;196(9):1304-12. doi: 10.1086/522428. Epub 2007 Oct 2. J Infect Dis. 2007. PMID: 17922394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page